
Sakditad Saowapa/X
Aug 6, 2025, 08:05
Sakditad Saowapa: Sunvozertinib Gains FDA Approval for Metastatic NSCLC
Sakditad Saowapa, Hematology-Oncology Fellow at the University of Iowa, shared a post on LinkedIn:
“FDA Accelerated Approval (2 Jul 2025)
Sunvozertinib (Zegfrovy) approved for metastatic NSCLC with EGFR exon 20 insertion after platinum chemotherapy.
- WU-KONG1B trial (n=85)
- ORR: 46% (95% CI: 35–57%)
- DoR: 11.1 months (95% CI: 8.2–NE)
- Companion Diagnosis: Oncomine Diagnosis Express Test
- Warnings: ILD/pneumonitis, GI, skin, ocular, embryo-toxic.”
More posts featuring Sakditad Saowapa.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 6, 2025, 08:05
Aug 6, 2025, 07:04
Aug 6, 2025, 06:42
Aug 6, 2025, 06:26
Aug 6, 2025, 05:59